Sugi Predict

Sugi Predict / Compounds / SCHEMBL645367

SCHEMBL645367

SCHEMBL645367

COc1ccc(Br)c(B(O)O)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ENPP2 Q13822 3/20 0.48
▸ CA1 P00915 3/20 0.48
▸ CA2 P00918 3/20 0.48
▸ CA12 O43570 2/20 0.40
▸ CA7 P43166 2/20 0.40
▸ CA9 Q16790 2/20 0.40
▸ CA14 Q9ULX7 2/20 0.40
▸ ERN1 O75460 1/20 0.40
▸ TRIM24 O15164 1/20 0.40
▸ TYR P14679 1/20 0.40
▸ TRIM33 Q9UPN9 1/20 0.40
▸ MAPT P10636 4/20 0.39
▸ RAB9A P51151 3/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP2A6 P11509 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ MEN1 O00255 3/20 0.38
▸ ALDH1A1 P00352 3/20 0.38
▸ KMT2A Q03164 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30154789 1.00 ENPP2 (0.48) ENPP2CA1CA2CA12CA7
SCHEMBL30250475 0.77 CA1 (0.53) CA1CA2CA12CA7CA9
SCHEMBL1134723 0.77 CA1 (0.53) CA1CA2CA12CA7CA9
SCHEMBL518510 0.77 TUBB4A (0.59) ENPP2CA1CA2CA12CA7
SCHEMBL1960037 0.77 ENPP2 (0.50) ENPP2CA1CA2CA12CA7
SCHEMBL29952460 0.77 ERN1 (0.55) ENPP2CA1CA2CA12CA7
SCHEMBL7238518 0.77 ERN1 (0.55) ENPP2CA1CA2CA12CA7
SCHEMBL29385414 0.77 TUBB4A (0.59) ENPP2CA1CA2CA12CA7
SCHEMBL41499 0.75 ENPP2 (0.48) ENPP2CA1CA2CA12CA7
SCHEMBL9935773 0.75 ENPP2 (0.48) ENPP2CA1CA2CA12CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116693566-A Preparation method of 2-bromo-5-methoxyphenylboronic acid 上海泰坦科技股份有限公司 2023-09-05 — — CN claimed
US-20250362134-A1 KRAS G12C INHIBITORS AND METHODS OF USING THE SAME AMGEN INC. (US) 2025-11-27 — — US disclosed
EP-3334430-B1 ATROPISOMERISM FOR INCREASED KINASE INHIBITOR SELECTIVITY SAN DIEGO STATE UNIV RESEARCH FOUNDATION (US) 2025-02-26 — — EP disclosed
US-20250057817-A1 KRAS G12C INHIBITORS AND METHODS OF USING THE SAME AMGEN INC. (US) 2025-02-20 — — US disclosed
CN-115626923-B KRAS G12C inhibitors and methods of use thereof 美国安进公司 2024-08-02 — — CN disclosed
US-20240174660-A1 KRAS G12C INHIBITORS AND METHODS OF USING THE SAME AMGEN INC. 2024-05-30 — — US disclosed
US-11905281-B2 KRAS G12C inhibitors and methods of using the same AMGEN INC. (US) 2024-02-20 — — US disclosed
US-20240050430-A1 KRAS G12C INHIBITORS AND METHODS OF USING THE SAME AMGEN INC. 2024-02-15 — — US disclosed
EP-3641776-B1 ATROPISOMERISM FOR ENHANCED KINASE INHIBITOR SELECTIVITY SAN DIEGO STATE UNIV RESEARCH FOUNDATION (US) 2023-10-18 — — EP disclosed
US-11766436-B2 KRAS G12C inhibitors and methods of using the same AMGEN INC. (US) 2023-09-26 — — US disclosed
US-7456176-B2 Benzotriazine inhibitors of kinases TARGEGEN, INC. (US) 2008-11-25 — — US disclosed
EP-1931669-A1 KINASE INHIBITORS Takeda San Diego, Inc. (US) 2008-06-18 — — EP disclosed
WO-2008054956-A2 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2008-05-08 — — WO disclosed
WO-2008045834-A2 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2008-04-17 — — WO disclosed
EP-1809614-A2 BENZOTRIAZINE INHIBITORS OF KINASES Targegen, Inc. (US) 2007-07-25 — — EP disclosed
US-20070117816-A1 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-05-24 — — US disclosed
US-20070117816-A1 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-05-24 — — US disclosed
WO-2007044779-A1 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2007-04-19 — — WO disclosed
US-20050245524-A1 Benzotriazine inhibitors of kinases TARGEGEN, INC. (US) 2005-11-03 — — US disclosed
WO-2005096784-A2 BENZOTRIAZINE INHIBITORS OF KINASES TARGEGEN, INC. (US) 2005-10-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240174660-A1 KRAS G12C INHIBITORS AND METHODS OF USING THE SAME KRAS, NRAS, HRAS ENPP2 698/4885CA1 2659/4885CA2 2465/4885
US-20070117816-A1 KINASE INHIBITORS MAP3K20, MAP3K19, MAP3K1 ENPP2 1685/4885CA1 3779/4885CA2 2138/4885
US-20050245524-A1 Benzotriazine inhibitors of kinases SRC, CAMK4, CAMK2G ENPP2 1856/4885CA1 3214/4885CA2 247/4885
US-20250057817-A1 KRAS G12C INHIBITORS AND METHODS OF USING THE SAME KRAS, NRAS, HRAS ENPP2 698/4885CA1 2659/4885CA2 2465/4885
US-20240050430-A1 KRAS G12C INHIBITORS AND METHODS OF USING THE SAME KRAS, NRAS, HRAS ENPP2 698/4885CA1 2659/4885CA2 2465/4885
US-11905281-B2 KRAS G12C inhibitors and methods of using the same KRAS, NRAS, HRAS ENPP2 698/4885CA1 2659/4885CA2 2465/4885
US-11766436-B2 KRAS G12C inhibitors and methods of using the same KRAS, NRAS, HRAS ENPP2 698/4885CA1 2659/4885CA2 2465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.